SELLAS Life Sciences Group Balance Sheet
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group financial position
At the end of fiscal 2025, SELLAS Life Sciences Group reported total assets of $78.3 million, up 303.2% from a year earlier against total liabilities of $7.5 million. Shareholders' equity stood at $70.9 million, or 90.5% of assets. The company held $71.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 71.79M | 13.89M | 2.53M | 17.13M | 21.36M | 35.30M | 7.28M | 5.34M | 2.32M | 5.96M |
| Receivables | — | — | — | — | 0 | — | — | — | — | — |
| Total Current Assets | 75.21M | 16.33M | 3.17M | 17.76M | 23.04M | 36.92M | 8.24M | 5.84M | 13.09M | 6.38M |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — | — | 199.00K |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 5.90M |
| Total Assets | 78.34M | 19.43M | 6.22M | 20.94M | 26.27M | 46.05M | 16.61M | 16.91M | 33.53M | 6.42M |
| Accounts Payable | 2.95M | 3.50M | 5.64M | 3.36M | 2.14M | 4.66M | 3.90M | 3.75M | 11.69M | 840.00K |
| Short-Term Debt | — | — | — | — | — | — | — | 0 | 8.38M | 16.40M |
| Total Current Liabilities | 7.02M | 9.51M | 13.73M | 15.52M | 4.98M | 12.34M | 5.29M | 5.97M | 24.57M | 5.76M |
| Long-Term Debt | — | — | — | — | — | — | — | 0 | 2.61M | — |
| Total Liabilities | 7.47M | 9.97M | 14.20M | 16.09M | 5.93M | 18.09M | 10.52M | 11.67M | 31.46M | 11.42M |
| Shareholders' Equity | 70.87M | 9.46M | -7.98M | 4.85M | 20.35M | 27.96M | 6.09M | 5.25M | 2.07M | -5.00M |
| Retained Earnings | -274.99M | -248.13M | -217.24M | -179.90M | -138.60M | -117.90M | -101.15M | -81.86M | -54.19M | -30.43M |
| Total Debt | — | — | — | — | — | — | — | 0 | 10.99M | 16.40M |
| Net Cash (Debt) | 71.79M | 13.89M | 2.53M | 17.13M | 21.36M | 35.30M | 7.28M | 5.34M | -8.67M | -10.44M |
| Shares Outstanding | 153.10M | 73.98M | 32.13M | 21.01M | 15.90M | 14.25M | 5.08M | 440.53K | 5.77M | 1.27M |
This table shows 10 annual periods of SELLAS Life Sciences Group's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow SLS's reporting calendar. What is a balance sheet?